Catalent And Ethicann Sign Development And License Agreement For New Fast-Dissolve Cannabinoid-Based Treatments
January 13, 2023
January 13, 2023
SOMERSET, New Jersey, Jan. 13 -- Catalent Inc., a pharma, biotech and consumer health company, issued the following news on Jan. 12, 2023:
Catalent, the global leader in enabling the development and supply of better treatments across multiple modalities, and Ethicann Pharmaceuticals Inc., a Canadian/U.S. specialty pharmaceutical company focused on the development of high-value cannabinoid drug therapies, today announced that the companies had executed a development and license agree . . .
Catalent, the global leader in enabling the development and supply of better treatments across multiple modalities, and Ethicann Pharmaceuticals Inc., a Canadian/U.S. specialty pharmaceutical company focused on the development of high-value cannabinoid drug therapies, today announced that the companies had executed a development and license agree . . .